Table 1.

DMARD treatment patterns for RA, PsA, or PsO patients following an initial CV event (N=9,529)

Treatment prior to CV eventNDMARD treatment persisted, n (%)DMARD treatment switched, n (%)All DMARDs treatment discontinued, n (%)
Entire study sample9,5296,985 (73.3%)1,498 (15.7%)1,046 (11.0%)
TNFi monotherapy1,7601,323 (75.2%)232 (13.2%)205 (11.6%)
TNFi + csDMARD combination therapy1,5141,160 (76.7%)299 (19.7%)55 (3.6%)
csDMARD monotherapy4,3693,320 (76.0%)528 (12.1%)521 (11.9%)
≥2 csDMARDs combination therapy808518 (64.1%)248 (30.7%)42 (5.2%)
Non-TNFi biologic monotherapy718445 (62.0%)63 (8.8%)210 (29.2%)
Non-TNFi biologic + csDMARD combination therapy360219 (60.8%)128 (35.6%)13 (3.6%)